Renatus is a pharmaceutical company whose mission is to provide safe and effective treatment options for the treatment of numerous cholesterol-driven diseases such as chronic kidney disease, atherosclerosis, and Alzheimer's diseases.
The core technology of the company allows normalization of cholesterol homeostasis by removal of excessive and toxic cholesterol within diseased cells without significant harmful effects on normal cells.
The lead asset RN-005 is a cholesterol metabolism modulator that has proven strong therapeutic efficacy in preclinical models of both diabetic kidney disease (DKD) and focal segmental glomerulosclerosis (FSGS) wherein dysregulated cholesterol metabolism causes progressive damage and loss of function in the kidney.
"I believe that cholesterol metabolism is a very promising therapeutic target in numerous diseases and Renatus is demonstrating it in the lab. Our aim is to translate the scientific discoveries into new drugs that can significantly improve the quality of lives of patients suffering from cholesterol-driven diseases."
- Dr. Heegon Kim, CEO of Renatus